07:00 Tue 29 Sep 2020
IXICO plc - >£2m contract extension win - Huntington’s disease
IXICO plc
("IXICO" or the "Company")
>
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, has executed a c.
This contract does not have significant impact on management's expectations of performance for the coming year, but will contribute to the Company's already strong order book for next year.
For further information please contact:
IXICO plc |
+44 (0)20 3763 7498 |
|||
|
|
|||
|
|
|||
Cenkos Securities PLC (Nominated adviser and sole broker) |
+44 (0)20 7397 8900 |
|||
|
|
|||
Michael F Johnson / |
|
|||
|
|
|||
Walbrook PR Ltd |
Tel: +44 (0)20 7933 8780 or IXICO@walbrookpr.com |
|||
|
|
|||
|
|
|||
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.
IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE